RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA MARKET ANALYSIS

Global relapsed or refractory diffuse large B cell lymphoma market is estimated to be valued at US$ 1,479.5 Mn in 2023 and is expected to exhibit a CAGR of 4.3% during the forecast period (2023-2030).

Analysts’ Views on Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market:

Increasing relapse and refractory cases of diffuse large B cell lymphoma (DLBCL)  are expected to drive  the global relapsed or refractory diffuse large B cell lymphoma market growth over the forecast period. This is expected to boost demand for innovative treatment options and contribute to the overall growth of the market. Furthermore, growing prevalence of DLBCL globally is also a significant factor contributing to market growth. Rising number of diagnosed cases necessitates the development of more effective therapies, thereby, boosting demand for innovative treatment options in the market. Advancements in medical research and technology enables discovery of novel therapeutic approaches for DLBCL, and this boosts demand for innovative treatment options. Moreover, increasing investments by pharmaceutical companies and government organizations for research and development activities related to DLBCL is expected to drive the market growth by facilitating the introduction of new and improved treatment options.

Figure 1. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market Share (%), By Drug Type, 2023

To learn more about this report, request a free sample copy

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market– Drivers

• Increasing incidence rate of R/R DLBCL: Diffuse large B cell lymphoma (DLBCL) is the most common type of non hodgkins lymphoma (NHL) that accounts forapproximately 31% of all NHL in Western countries and 37% of B-cell tumors worldwide. The median age at presentation is 66, however, DLBCL can occur at any age. There is a slightly higher incidence in men (6.7 vs 4.6 cases per 100,000 persons, male vs female). The probability of having DLBCL increases with age, from 0.13% and 0.09% before the age of 39 to 1.77% and 1.4% after the age of 70 in men and women, respectively. 5-year survival rates decrease by age from 78% for those aged <55 years to 54% for those aged ≥ 65 years.

Figure 2. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market Share(%), By Region, 2023

To learn more about this report, request a free sample copy

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Regional Analysis

• Among regions, North America is estimated to hold a dominant position in the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. North America is estimated to hold 39.1% of the market share in 2023. The market is expected to witness significant growth in the near futuresdue to high incidence rate of r/r DLBCL. In 2021, the incidence rate of NHL in the U.S  was estimated at 19.6 cases per 100,000 per year. In 2020, an estimated 73,652 new NHL cases were reported in the U.S For DLBCL specifically, the estimated incidence rate is 4.68 cases per 100,000 per year in the U.S.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization (WHO) declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding  the transportation of things from one place to another.
• However, the COVID-19 pandemic had negative impact on the global relapsed or refractory diffuse large B cell lymphoma market, owing to reduction in the bed and operating room capacity that led to considerable in the treatment.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market Segmentation:

Global relapsed or refractory diffuse large B cell lymphoma market  is segmented into  drug type, distribution channel, and region.

• By drug type, the market is segmented into monjuvi, XPOVIO, polivy, kymriah, yescarta, and others. Out of which, the monjuvi segment is expected to hold a dominant position in the global relapsed or refractory diffuse large B cell lymphoma market during the forecast period owing to increasing acceptance of monjuvi for the treatment of R/R DLBCL.
• By distribution channel, the market is segmented into hospitals pharmacies, retail pharmacies, and online pharmacies. Out of which, hospitals pharmacies is expected to dominate the market over the forecast period owing as  prompt treatment that can lead to proper recovery.
• Among all the segmentation, the drug type segment is expected to dominate the market over the forecast period owing to increasing preference of drugs for the permanent solution of R/R DLBCL.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market- Cross Sectional Analysis:

Key players are making relapsed or refractory diffuse large B cell lymphoma with combination of drug which is expected to drive the relapsed or refractory diffuse large B cell lymphoma market in North America region. For instance, in April 2021, Eagle Pharmaceuticals, Inc., a pharmaceutical company with research and development, clinical, manufacturing and commercial expertise, announced that TREAKISYM ready-to-dilute (“RTD”) (bendamustine hydrochloride 120 mg/m2) liquid formulation had  been approved for a new indication in combination with rituximab (“BR therapy”) as treatment for relapsed or refractory diffuse large B-cell lymphoma (“r/r DLBCL”) by the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market: Key Developments

• In June 2022, Bristol-Myers Squibb Company, a global biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with large B-cell lymphoma (LBCL) including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplant (HSCT) due to comorbidities or age
• In December 2022, Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the launch of its clonoSEQ Assay to detect minimal residual disease (MRD) in blood for patients with diffuse large B-cell lymphoma (DLBCL). DLBCL is the most common type of non-Hodgkin lymphoma (NHL), affecting more than 100,000 people in the U.S. Disease monitoring is crucial to patient management because DLBCL is an aggressive condition that many patients may be able to recover from.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market: Key Trends

• Introduction of relapsed or refractory diffuse large B cell lymphoma drug with advanced technology: Introduction of relapsed or refractory diffuse large B cell lymphoma drug with advanced technology in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. For instance, on July 11, 2023, Roche, a multinational healthcare company, announced that the European Commission (EC) had granted conditional marketing authorization for Columvi (glofitamab) for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. With this approval, Columvi is the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with the most common and aggressive form of lymphoma following multiple lines of therapy. Columvi has the potential to change the current standard of care in DLBCL. As well as inducing early and long-lasting responses in people with heavily pre-treated or refractory DLBCL, Columvi is designed to be provided for a fixed period of time meaning that people have a target end date for their course of treatment and the possibility of a treatment-free period. It is also a chemotherapy-free treatment option that is off-the-shelf, meaning that people do not have to wait for cell collection and genetic engineering - a multistep process that can take several weeks - before starting treatment. This could be particularly important for patients who are at a high-risk of their disease progressing.

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market: Restraint

• Treatment challenges for the geriatric patient group: Geriatric patients have decreased tolerance of chemotherapy because of limited bone marrow reserve, altered drug metabolism, presence of comorbid conditions, or impaired physical function and/or cognition. Resulting concerns may lead to application of attenuated regimens or withholding curative therapy based on age alone, which may not always be well-justified clinically.
• Counterbalance: Key players are focusing on developing advanced products with safety and cost effective for geriatric patient

Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market - Key Players

Major players operating in the global relapsed or refractory diffuse large B cell lymphoma market include MorphoSys U.S. Inc., Bristol Myers Squibb, Karyopharm Therapeutics, Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation.

*Definition: Diffuse large B-cell lymphoma (DLBCL) is a fast-growing blood cancer. Healthcare providers typically treat this condition with a combination of cancer drugs. The combined drugs often eliminate DLBCL signs and symptoms and cure the condition. Medical researchers are studying different treatments for DLBCL that don’t respond to treatment or regenerate.